Jump to content

Radiation Oncology/Supportive care/Diarrhea

Add links
From Wikibooks, open books for an open world
< Radiation Oncology | Supportive care
This page may need to be reviewed for quality.


Diarrhea



Prophylaxis:

  • 5-ASA drugs (oral):
    • Mesalamine (Asacol, Pentasa) - is 5-ASA without side chains
    • Sulfasalazine (Azulfidine) - 500 mg BID
    • Balsalazide (Colazal) - 3 x 750 mg tabs BID (i.e. 2250 mg twice a day)
      • Prodrug cleaved in the colon to mesalamine.
    • Olsalazine - 2 5-ASA molecules bound
  • 5-ASA enemas, foams


Selenium

  • Lippe Hospital, Germany (2000-2006) -- selenium vs control
    • Randomized. 81 patients with uterine (88%) or cervical (12%) cancer. If pretreatment selenium <84 ug/l randomized to Arm 1) selenium 500 ug PO daily vs Arm 2) control. Primary endpoint: efficiency of supplementation
    • 2010 PMID 20133068 -- "Multicenter, Phase 3 Trial Comparing Selenium Supplementation With Observation in Gynecologic Radiation Oncology." (Muecke R, Int J Radiat Oncol Biol Phys. 2010 Feb 2. [Epub ahead of print])
      • Outcome: Selenium level post RT significantly higher with supplement. Grade 2+ diarrhea selenium 20% vs no selenium 44% (SS). No difference in other measures
      • Conclusion: Selenium supplementation effective in improving blood selenium status in deficient patients, and reduces RT-induced diarrhea


Octreotide

  • RTOG 0315 (2003-2006) -- octreotide vs placebo
    • Randomized. 215 patients, rectal or anal cancer. Arm 1) long-acting octreotide 30 mg given 4-7 days before RT, and again day 22 vs Arm 2) placebo. Primary endpoint Grade 2+ diarrhea
    • 2010 PMID 20339140 -- "Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315." (Zachariah B, J Natl Cancer Inst. 2010 Apr 21;102(8):547-56. Epub 2010 Mar 25.) Median F/U 10 months
      • Outcome: Grade 2-4 acute diarrhea octreotide 44% vs placebo 49% (NS). No difference in chemotherapy delivery, RT delivery, medical resource utilization, bowel function or QoL
      • Conclusion: Prophylactic use of octreotide had no benefit


Guidelines:

  • For gastrointestinal mucositis - PMID 15108223 Full text — "Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis." Rubenstein EB et al. Cancer. 2004 May 1;100(9 Suppl):2026-46.
Retrieved from "https://en.wikibooks.org/wiki/Radiation_Oncology/Supportive_care/Diarrhea"